You can't take a GLP-1, and every headline you've read this year is about Ozempic and Zepbound. This guide ranks the real, FDA-approved alternatives for patients with a genuine contraindication or a compliance reason to skip GLP-1 therapy in 2026.
TL;DR
- Contrave (naltrexone-bupropion) produced 6.1% weight loss at 56 weeks in the COR-I trial versus 1.3% on placebo. Buy for most non-GLP-1 candidates.
- Qsymia (phentermine-topiramate ER) hit 10.9% average loss at the top dose in the EQUIP trial, the strongest non-GLP-1 result available. Consider if you tolerate stimulants.
- Phentermine alone is FDA-labeled for short-term use only, capped around 12 weeks. Use as a bridge, not a plan.
- Orlistat delivered just 3.05 kg more loss than placebo over 4 years in the XENDOS trial. Skip unless GI tolerance rules out everything else.
- Metformin is not a weight loss drug on its own, but it earns a place for patients with insulin resistance or PCOS. Consider as an adjunct, not a standalone.
- Contrave produced 6.1% weight loss at 56 weeks versus 1.3% on placebo (COR-I trial) — a "Buy" verdict for most non-GLP-1 candidates.
- Qsymia hit 10.9% average loss at the top dose (EQUIP trial), the strongest non-GLP-1 result available.
- Phentermine alone is FDA-labeled for short-term use only, generally capped around 12 weeks.
- Orlistat added just 3.05 kg over placebo across four years in the XENDOS trial — the weakest result on this list.
- Metformin isn't FDA-approved for weight loss but earns a place as an adjunct for insulin resistance or PCOS.
- GoodLife Health bills medication at pharmacy cost with no markup, on top of one flat $299 monthly membership.
Why this matters
GLP-1 drugs get contraindicated for real reasons: a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, severe gastroparesis, pregnancy, or a documented hypersensitivity reaction. Some patients simply can't tolerate the GI side effects even after slow titration. None of that means weight loss treatment stops. It means the treatment plan needs to be built around a different molecule and, more importantly, around the same labs.
GLP-1 contraindications include a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, severe gastroparesis, pregnancy, or a documented hypersensitivity reaction. Some patients simply can't tolerate the GI side effects even after slow titration.
That's the mistake most weight loss platforms make when a patient can't take a GLP-1: they either shrug and offer nothing, or they push a stimulant with no lab oversight. Metabolic syndrome, insulin resistance, thyroid function, and cardiovascular risk markers don't disappear just because the medication changed. Phentermine for adults who don't qualify for GLP-1 medications works completely differently for a patient with normal ApoB than it does for a patient whose lipid panel already flags cardiovascular risk, and a clinician who isn't tracking those numbers every 90 days is guessing.
GoodLife Health treats this as a Cardiometabolic Optimization problem, not a prescription-swap problem. The medication changes; the biomarker-guided protocol doesn't.
Metabolic syndrome, insulin resistance, thyroid function, and cardiovascular risk markers don't disappear just because the medication changed.
How we ranked these
Every medication below is ranked on four factors: FDA approval status for chronic weight management (not off-label guesswork), average weight loss reported in peer-reviewed trials, the burden of side effects and monitoring, and how well it fits alongside the labs a patient with a GLP-1 contraindication typically needs tracked anyway (lipids, HbA1c, blood pressure, liver enzymes). Trial data is cited by name and year throughout, based on aggregated published results, not patient-reported anecdotes. Individual results vary, and none of these medications work without the diet and activity changes that make any pharmacologic tool effective.
The ranked list
1. Qsymia (phentermine-topiramate ER) — the strongest number on paper
Qsymia combines low-dose phentermine with extended-release topiramate, an anticonvulsant that independently reduces appetite and food cravings. In the EQUIP trial (2012), patients on the top dose averaged 10.9% weight loss over one year, the best result of any non-GLP-1 medication with FDA approval for chronic weight management.
The catch: it's dispensed through a restricted REMS pharmacy program, it's contraindicated in glaucoma and hyperthyroidism, and topiramate carries a real risk of cognitive fog and kidney stones at higher doses. It also carries a pregnancy warning due to cleft palate risk, so it's a poor fit for anyone planning pregnancy. Verdict: Consider, specifically for patients without glaucoma, thyroid disease, or pregnancy plans who want the highest-efficacy non-GLP-1 option.
2. Contrave (naltrexone-bupropion) — the mood-and-appetite dual mechanism
Contrave pairs an opioid antagonist with an antidepressant, targeting the brain's reward pathway around food rather than gut hormones. The COR-I trial (2010) recorded 6.1% average weight loss at 56 weeks versus 1.3% on placebo, a modest but consistent result across a large trial population.
It's a reasonable option for patients who also carry mild depression or a history of smoking cessation attempts, since bupropion does double duty. It's contraindicated in uncontrolled hypertension and seizure disorders. Contrave for weight loss alongside medical supervision walks through dosing titration and the blood pressure checks that should accompany it. Verdict: Buy for patients without seizure or hypertension contraindications who want steady, monitored results.
3. Phentermine alone — the short-term bridge
Phentermine is the oldest weight-loss stimulant still in wide use, and the FDA label still restricts it to short-term use, generally interpreted as up to 12 weeks. Older trial data going back decades reported 5-10% weight loss over that window, though modern comparative data against newer agents is limited.
It's cheap, fast-acting, and effective as a jump-start, but it isn't a maintenance drug. Patients who stop after 12 weeks without a follow-on plan tend to regain. Verdict: Consider as a bridge into a longer-term protocol, never as the whole plan.
4. Orlistat (Xenical / Alli) — the fat-blocker with a GI cost
Orlistat blocks roughly 30% of dietary fat absorption in the gut. The XENDOS trial (2004), one of the longest weight-loss drug trials ever run at four years, showed only 3.05 kg more weight loss than placebo over that period, alongside a meaningfully lower rate of progression to type 2 diabetes.
The tradeoff is GI side effects that are hard to overstate: oily stool, urgency, and fecal incontinence on higher-fat meals. It also blocks absorption of fat-soluble vitamins, which needs supplementation. Verdict: Skip for most patients; the efficacy is the weakest on this list and the tolerability issues drive high discontinuation rates.
5. Metformin — the metabolic adjunct, not a standalone
Metformin isn't FDA-approved for weight loss and isn't marketed as one. It's an insulin-sensitizing drug that produces modest weight loss, typically in the 2-3% range, mostly in patients who start with elevated fasting insulin or a PCOS diagnosis.
Where it earns a spot: patients with insulin resistance on their labs who can't take a GLP-1 still benefit from lowering circulating insulin, which is part of the same cardiometabolic picture as weight. Verdict: Consider as an adjunct alongside another agent on this list, guided by fasting insulin and HbA1c, not as a primary weight-loss drug.
6. Setmelanotide (Imcivree) — the genetic-condition specialist
Setmelanotide is FDA-approved only for obesity caused by confirmed genetic deficiencies in POMC, PCSK1, or LEPR, or for Bardet-Biedl syndrome. It's not a general-population weight loss medication and requires genetic testing to confirm eligibility.
For the narrow group of patients it's approved for, trial data showed substantial and durable weight loss. For everyone else, it's simply not an option. Verdict: Consider only with confirmed genetic testing; skip without it.
Comparison table
Non-GLP-1 Weight Loss Medications Compared
Ranked by FDA approval, trial data, and monitoring fit
| Medication | Mechanism | Trial result | Best for | Verdict |
|---|---|---|---|---|
| Qsymia | Phentermine + topiramate ER | 10.9% at 1 year (EQUIP, 2012) | Highest efficacy, no glaucoma/thyroid history | Consider |
| Contrave | Naltrexone + bupropion | 6.1% at 56 weeks (COR-I, 2010) | Mild depression, no seizure history | Buy |
| Phentermine | Stimulant appetite suppressant | 5-10% over ~12 weeks (older data) | Short-term jump-start only | Consider |
| Orlistat | Fat absorption blocker | 3.05 kg over placebo at 4 years (XENDOS, 2004) | High fat-tolerance patients | Skip |
| Metformin | Insulin sensitizer | ~2-3%, adjunct only | Insulin resistance, PCOS | Consider (adjunct) |
| Setmelanotide | MC4R pathway agonist | Substantial in genetic obesity only | Confirmed POMC/PCSK1/LEPR deficiency | Consider only if tested |
Where to get these prescribed
None of these are supplements, and none belong on a wellness storefront that skips your labs. Three rules matter in 2026 more than they did five years ago, as compounded and unregulated weight-loss channels have multiplied:
- Insist on a lab review before the prescription, not after. A clinician who prescribes Contrave without checking your blood pressure history, or Qsymia without asking about glaucoma, is skipping the part of the visit that actually matters.
- Confirm the price is flat, not dose-escalating. Some platforms quietly raise the monthly fee as your dose increases. GoodLife Health's model bills medication at pharmacy cost with no markup and no dose-escalation fee, on top of one flat $299 monthly membership. One flat fee for the doctor. Zero markup on the medicine.
- Ask who reviews your labs on an ongoing basis. A single intake call isn't monitoring. Direct primary care for weight loss management explains what a quarterly Biomarker Audit actually tracks across lipids, HbA1c, and inflammation markers, which matters even more when the medication itself doesn't touch appetite hormones the way a GLP-1 does.
If you've already tried a GLP-1 and stopped due to side effects rather than a hard contraindication, it's worth reviewing best GLP-1 medications for weight loss in 2026 before ruling the entire drug class out — dose titration and drug choice within the class (Wegovy versus Zepbound versus oral Foundayo) solve a meaningful share of tolerability complaints.
FAQ
What are the best weight loss medications without GLP-1?
Qsymia (phentermine-topiramate ER) and Contrave (naltrexone-bupropion) are the two FDA-approved options with the strongest trial data, at 10.9% and 6.1% average weight loss respectively. Phentermine alone works as a short-term bridge, and metformin helps as an adjunct for patients with insulin resistance.
Why can't some patients take GLP-1 medications?
Common contraindications include a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, severe gastroparesis, pregnancy, or a documented allergic reaction. Some patients also can't tolerate the GI side effects even after slow dose titration.
Is Contrave as effective as Ozempic?
No. Contrave averaged 6.1% weight loss in the COR-I trial, while semaglutide (Ozempic/Wegovy) averaged around 15% in the STEP-1 trial. Contrave is the alternative for patients who cannot take a GLP-1, not an equal substitute.
How much weight can you lose on Qsymia?
Patients on the top dose of Qsymia averaged 10.9% weight loss over one year in the EQUIP trial (2012). It's the highest average result among FDA-approved non-GLP-1 weight loss medications, though individual results vary.
Is orlistat worth trying for weight loss?
For most patients, no. The XENDOS trial found only 3.05 kg more weight loss than placebo over four years, and the GI side effects, including oily stool and urgency, drive high discontinuation rates.
Can metformin help with weight loss if I can't take a GLP-1?
Metformin isn't FDA-approved for weight loss on its own, but it produces modest loss (roughly 2-3%) in patients with insulin resistance or PCOS. It works best as an adjunct alongside another agent, guided by fasting insulin and HbA1c labs.
**Are compounded weight loss medications a safe altern
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/